NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC for TEVA PHARMACUETICALS USA
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
preemption for ANDA holders under Hatch-Waxman; R&D tax credit; generic biologics; patent settlements
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DALE MCMICKLE New | Senate Judiciary Committee, Counsel |
Health Issues HCR
preemption for ANDA holders under Hatch-Waxman; R&D tax credit; generic biologics; patent settlements
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DALE MCMICKLE New | Senate Judiciary Committee, Counsel |
Pharmacy PHA
preemption for ANDA holders under Hatch-Waxman; R&D tax credit; generic biologics; patent settlements
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DALE MCMICKLE New | Senate Judiciary Committee, Counsel |
Torts TOR
preemption for ANDA holders under Hatch-Waxman; R&D tax credit; generic biologics; patent settlements
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DALE MCMICKLE New | Senate Judiciary Committee, Counsel |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| TEVA PHARMACETICALS INDUSTRIES, LTD | Israel | Israel | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.